Free Trial

EUDA Health (EUDA) Competitors

EUDA Health logo
$4.00 -0.04 (-0.99%)
As of 02:24 PM Eastern

EUDA vs. EHAB, INNV, CELC, PSNL, VMD, DCGO, LFMD, TOI, SERA, and AIRS

Should you be buying EUDA Health stock or one of its competitors? The main competitors of EUDA Health include Enhabit (EHAB), InnovAge (INNV), Celcuity (CELC), Personalis (PSNL), Viemed Healthcare (VMD), DocGo (DCGO), LifeMD (LFMD), Oncology Institute (TOI), Sera Prognostics (SERA), and AirSculpt Technologies (AIRS). These companies are all part of the "healthcare" industry.

EUDA Health vs.

EUDA Health (NASDAQ:EUDA) and Enhabit (NYSE:EHAB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, community ranking, media sentiment, dividends, valuation, analyst recommendations and profitability.

In the previous week, Enhabit had 1 more articles in the media than EUDA Health. MarketBeat recorded 2 mentions for Enhabit and 1 mentions for EUDA Health. Enhabit's average media sentiment score of 1.13 beat EUDA Health's score of 0.46 indicating that Enhabit is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
EUDA Health
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Enhabit
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

4.3% of EUDA Health shares are owned by institutional investors. 1.9% of Enhabit shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

EUDA Health has higher earnings, but lower revenue than Enhabit.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EUDA Health$3.81M25.85-$10.04MN/AN/A
Enhabit$1.03B0.35-$80.50M-$3.11-2.33

EUDA Health has a beta of -0.05, suggesting that its share price is 105% less volatile than the S&P 500. Comparatively, Enhabit has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500.

Enhabit received 4 more outperform votes than EUDA Health when rated by MarketBeat users. However, 100.00% of users gave EUDA Health an outperform vote while only 17.24% of users gave Enhabit an outperform vote.

CompanyUnderperformOutperform
EUDA HealthOutperform Votes
1
100.00%
Underperform Votes
No Votes
EnhabitOutperform Votes
5
17.24%
Underperform Votes
24
82.76%

EUDA Health has a net margin of 0.00% compared to Enhabit's net margin of -11.24%. Enhabit's return on equity of 1.67% beat EUDA Health's return on equity.

Company Net Margins Return on Equity Return on Assets
EUDA HealthN/A N/A N/A
Enhabit -11.24%1.67%0.80%

Enhabit has a consensus target price of $8.50, suggesting a potential upside of 17.40%. Given Enhabit's higher possible upside, analysts plainly believe Enhabit is more favorable than EUDA Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EUDA Health
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
4.00
Enhabit
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Enhabit beats EUDA Health on 10 of the 17 factors compared between the two stocks.

Get EUDA Health News Delivered to You Automatically

Sign up to receive the latest news and ratings for EUDA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EUDA vs. The Competition

MetricEUDA HealthHealth services IndustryMedical SectorNASDAQ Exchange
Market Cap$98.51M$844.01M$5.22B$7.09B
Dividend YieldN/A2.59%5.45%4.34%
P/E RatioN/A47.8021.6917.48
Price / Sales25.857.64379.5395.52
Price / CashN/A26.1438.2534.62
Price / Book-13.333.996.403.88
Net Income-$10.04M-$5.50M$3.21B$247.27M
7 Day Performance-2.44%-0.78%0.56%-0.26%
1 Month Performance-1.48%-0.05%-9.88%-8.42%
1 Year Performance128.57%61.49%11.61%-0.24%

EUDA Health Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EUDA
EUDA Health
0.4567 of 5 stars
$4.00
-1.0%
N/A+130.9%$98.51M$3.81M0.002
EHAB
Enhabit
1.9017 of 5 stars
$7.77
+0.1%
$8.50
+9.4%
-25.1%$391.73M$1.03B-3.3510,800Positive News
INNV
InnovAge
1.7608 of 5 stars
$2.83
+0.4%
$5.00
+76.7%
-30.4%$382.74M$806.61M-14.892,000Short Interest ↓
News Coverage
Positive News
Gap Up
CELC
Celcuity
1.6737 of 5 stars
$9.75
+5.6%
$30.17
+209.4%
-40.6%$368.93MN/A-3.7440
PSNL
Personalis
3.8265 of 5 stars
$3.24
-1.2%
$7.80
+140.7%
+147.3%$286.12M$84.61M-1.93400News Coverage
VMD
Viemed Healthcare
1.0161 of 5 stars
$6.59
-0.3%
N/A-15.9%$261.24M$224.26M24.41630Short Interest ↑
DCGO
DocGo
2.9661 of 5 stars
$2.35
-1.7%
$4.89
+108.2%
-40.6%$239.66M$616.56M8.392,920Positive News
LFMD
LifeMD
2.2008 of 5 stars
$5.13
+2.0%
$11.43
+122.8%
-44.0%$224.26M$212.45M-8.02230Positive News
TOI
Oncology Institute
0.2816 of 5 stars
$1.95
+8.9%
N/A+81.5%$147.34M$393.41M-2.50660High Trading Volume
SERA
Sera Prognostics
0.5116 of 5 stars
$3.34
+2.8%
N/A-65.1%$122.41M$77,000.00-3.37120News Coverage
AIRS
AirSculpt Technologies
1.0482 of 5 stars
$1.78
-2.5%
$3.75
+111.3%
-70.2%$106.61M$180.35M-12.68240Upcoming Earnings
Negative News
Gap Down
High Trading Volume

Related Companies and Tools


This page (NASDAQ:EUDA) was last updated on 4/21/2025 by MarketBeat.com Staff
From Our Partners